GP方案与TP方案治疗晚期非小细胞肺癌的比较

目的探讨GP方案和TP方案对初治的晚期非小细胞肺癌（NSCLC）的疗效和毒性。方法70例初治晚期NSCLC患者随机分为TP组（36例）和GP组（34例）。TP组：紫杉醇135mg／m^2，第1天；顺铂30mg／m^2，第1-3天。GP组：吉西他滨1000mg／m^2,第1、8天；顺铂30mg／m^2，第1-3天。化疗2-3个周期后对两组的临床疗效和毒性反应进行评价。结果GP和TP两组的有效率分别为44．4％（16／36）和35．3％（12134），两组中位生存期分别为8．7个月和8．5个月，1年生存率分别为16．6％和19．4％，2年生存率分别为8．3％和11．1％。两组资料统计学处理均无显著性差异。毒副反应方面，GP组以血小板降低为主，TP组以白细胞降低为主，均在可耐受的范围内。结论GP方案和TP方案对晚期NSCLC疗效肯定，不良反应有一定差异，可根据不同个体选用不同的化疗方案。

A Comparison between GP Regimen and TP Regimen in Patients with Advanced Non-small Cell Lung Cancer by Different Chemotherapy

Objective To investigate the efficacy and toxicity of the GP regimen and TP regimen on advanced non-small cell lung cancer. Methods Seventy advanced NSCLC patients were randomly divided into two groups,36 in TP group and 34 in GP group. TP group：paclitaxel 135 mg/m^2,on day 1;cisplatin 30 mg/m^2,on days 1-3. GP group：gemcitabine1000mg/m^2, on days 1,8; cisplatin 30 mg/m^2,on days 1 - 3. Results The short term effective rate for advanced non-small cell lung cancer in GP group and TP group was 44.4%（16/36） and 35.3%（12/34）, respectively.The median survival time was 8.7 months and 8.5 months,respectively. 1-year survival rate was 16.6% and 19.4%, respectively. 2-year survival rate was 8.3% and 11.1%. The short term effectiveness and the 1,2-year-survival rate in two groups had no statistically significant difference（P〉0.05）. In the adverse effects of treatment, the major cytotoxicity was thrombocytopenia in GP group and leukopenia in TP group but they were tolerable. Conclusion The curetive effect of GP regimen and TP regimen are affirmed, there are certain differences in adverse reactions. Different themes can be chosen according to different choice in patients with advanced non-small cell lung cancer.